Cheng 2003.
Methods | Parallel design Aim: to treat depression and augment rehabilitation Analysis: according to allocated treatment group |
|
Participants | Location: China Setting: inpatient Treatment: 25 people Control: 32 people Whole group (including non‐depression group, depression control group and depression treatment group): 132 (mean age 62 ± 12 years, 79 men) Stroke: ischaemic stroke or PICH, clinical diagnosis plus confirmation on brain imaging (not clear that a stroke lesion had to be present), clear consciousness Depression diagnosis (at 2 weeks after stroke onset): psychiatric interview, DSM IV criteria Excluded: major psychological trauma history in previous 1 year, severe mental retardation, severe impairment of lingual expression or comprehension, major complicated medical event in previous 1 year |
|
Interventions | Treatment: fluoxetine 20 mg daily Control: no fluoxetine Duration of treatment: 6 months Duration of follow‐up (post‐treatment to study end): 6 months |
|
Outcomes | SSS ADL HAMD Zung SDS Zung SAS No deaths, none left trial early No data on AEs |
|
Funding source | No description of funding | |
Notes | − | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Method not described |
Allocation concealment (selection bias) | Unclear risk | Not described |
Blinding of participants and personnel (performance bias) All outcomes | High risk | No placebo |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Not described |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | 59 participants were diagnosed to have depression by symptoms but only 57 were included in the results table |
Selective reporting (reporting bias) | High risk | No protocol, no report of the results of the self‐rating anxiety scale |
Other bias | Unclear risk | No clear description of differences between the treatment and control group |